Drug Trial Radar · NCT07288216
Transition to KPL-387 Monotherapy Dosing & Administration Study
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 25, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Kiniksa Pharmaceuticals International, plcIndustry
- Sponsor type
- Industry
- Collaborators
- Kiniksa Pharmaceuticals, GmbH
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Conditions
- Recurrent Pericarditis
- Heart Diseases
- Pericarditis
Interventions
KPL-387Drug
administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Posology: Proportion of participants free from Pericarditis Recurrence by Week 16Time frame: From baseline up to Week 16
- Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE.Time frame: Up to 24 Months
Locations
48 sites in 10 countries. Site status is shown where the registry gives one.
Investigational Site 031
Phoenix, Arizona · Recruiting
Investigational Site 045
La Jolla, California · Recruiting
Investigational Site 014
Los Angeles, California · Recruiting
Investigational Site 002
Santa Monica, California · Recruiting
Investigational Site 046
Washington D.C., District of Columbia · Recruiting
Investigational Site 039
Jacksonville, Florida · Recruiting
Investigational Site 013
Chicago, Illinois · Recruiting
Investigational Site 025
Baltimore, Maryland · Recruiting
Investigational Site 043
Boston, Massachusetts · Recruiting
Investigational Site 028
Rochester, Minnesota · Recruiting
Investigational Site 042
St Louis, Missouri · Recruiting
Investigational Site 011
New York, New York · Recruiting
Investigational Site 003
New York, New York · Recruiting
Investigational Site 009
Cincinnati, Ohio · Recruiting
Investigational Site 040
Cleveland, Ohio · Recruiting
Investigational Site 005
Austin, Texas · Recruiting
Investigational Site 047
Dallas, Texas · Recruiting
Investigational Site 006
Houston, Texas · Recruiting
Investigational Site 004
Charlottesville, Virginia · Recruiting
Investigational Site 001
Norfolk, Virginia · Recruiting
Investigational Site 008
Richmond, Virginia · Recruiting
Investigational Site 010
Ottawa, Ontario, Canada · Recruiting
Investigational Site 027
Paris, France · Recruiting
Investigational Site 026
Poitiers, France · Recruiting
Investigational Site 032
Toulouse, France · Recruiting
Investigational Site 038
Toulouse, France · Recruiting
Investigational Site 041
Dresden, Germany · Recruiting
Investigational Site 035
Athens, Greece · Recruiting
Investigational Site 023
Nea Ionia, Greece · Recruiting
Investigational Site 024
Voula, Greece · Recruiting
Investigational Site 044
Florence, Italy · Recruiting
Investigational Site 034
Genoa, Italy · Recruiting
Investigational Site 021
Milan, Italy · Recruiting
Investigational Site 036
Padua, Italy · Recruiting
Investigational Site 033
Udine, Italy · Recruiting
Investigational Site 037
Varese, Italy · Recruiting
Investigational Site 048
Warsaw, Poland · Recruiting
Investigational Site 020
Warsaw, Poland · Recruiting
Investigational Site 030
Belgrade, Serbia · Recruiting
Investigational Site 029
Belgrade, Serbia · Recruiting
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.